Sugi Predict

Sugi Predict / Targets / ACOT7

ACOT7

Cytosolic acyl coenzyme A thioester hydrolase · O00154 · ACOT7 on Sugi Atlas →

21 patent compounds predicted against ACOT7, 17 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL21943538 SCHEMBL21943538 0.59 1/20
SCHEMBL21943762 SCHEMBL21943762 0.57 1/20
SCHEMBL21944043 SCHEMBL21944043 0.55 1/20
SCHEMBL21943004 SCHEMBL21943004 0.55 1/20
SCHEMBL21942995 SCHEMBL21942995 0.53 1/20
SCHEMBL21943411 SCHEMBL21943411 0.53 1/20
SCHEMBL14042267 SCHEMBL14042267 0.52 1/20
SCHEMBL21943429 SCHEMBL21943429 0.52 1/20
SCHEMBL22066328 SCHEMBL22066328 0.51 1/20
SCHEMBL21943540 SCHEMBL21943540 0.49 1/20
SCHEMBL21943537 SCHEMBL21943537 0.45 1/20
SCHEMBL24016281 SCHEMBL24016281 0.44 1/20
SCHEMBL24532074 SCHEMBL24532074 0.42 1/20
SCHEMBL1454562 SCHEMBL1454562 0.42 1/20
SCHEMBL17612956 SCHEMBL17612956 0.42 1/20
SCHEMBL12399198 SCHEMBL12399198 0.42 1/20
SCHEMBL29911712 SCHEMBL29911712 0.40 1/20

Clinical trials — most relevant to ACOT7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis PHASE4COMPLETED
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease PHASE2COMPLETED
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients PHASE2COMPLETED
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC PHASE1/PHASE2UNKNOWN
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis PHASE2UNKNOWN
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma PHASE2COMPLETED
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy PHASE2RECRUITING
Cholic Acid for Hepatic Steatosis in Lipodystrophy PHASE2COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes nanCOMPLETED
Phenotypic and Genotypic Studies in Congenital and Early Onset Ataxias nanCOMPLETED
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Epidemiology of Atherosclerosis nanCOMPLETED
Fatty Acid Oxidation Defects and Insulin Sensitivity nanCOMPLETED
A Prospective Study of the Disease Characteristics of Adult Patients With Long Chain Fatty Acid Oxidation Disorders nanCOMPLETED
Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise nanCOMPLETED
Systemic Biomarkers of Brain Injury From Hyperammonemia nanRECRUITING
Genetic and Environmental Determinants of Triglycerides (GOLDN) nanCOMPLETED
Familial Partial Lipodystrophy Study nanCOMPLETED
Investigations Into ISCU Myopathy or Iron Sulfur Scaffold U Protein Myopathy nanCOMPLETED
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children nanWITHDRAWN
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population nanUNKNOWN
Genetic Origin of Lipid Disorders nanUNKNOWN
Lipodystrophy Connect Patient Registry nanCOMPLETED
Role of Dairy Products in Weight Maintenance nanCOMPLETED
RCDP Natural History Study nanUNKNOWN
Identification of a New Gene Involved in Hereditary Lipodystrophy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ACOT7 binder may also engage these)

ProteinNameSimilarity
Q91V12 — 1.000 Q91V12 →
Q64559 — 1.000 Q64559 →
Q03555 — 0.917 Q03555 →
Q9PW38 — 0.916 Q9PW38 →
Q8BUV3 — 0.915 Q8BUV3 →
Q5NVN7 — 0.910 Q5NVN7 →
WDR26 WD repeat-containing protein 26 0.909 landscape →
Q9NQX3 — 0.908 Q9NQX3 →
Q8C6G8 — 0.908 Q8C6G8 →
SAE1 SUMO-activating enzyme subunit 1 0.908 landscape →
GLS Glutaminase kidney isoform, mitochondrial 0.908 landscape →
Q5R4Q7 — 0.906 Q5R4Q7 →
Q5VU57 — 0.905 Q5VU57 →
Q5RKN4 — 0.905 Q5RKN4 →
D3Z7P3 — 0.904 D3Z7P3 →
Q8N653 — 0.903 Q8N653 →
P13264 — 0.903 P13264 →
Q5R5K6 — 0.903 Q5R5K6 →
Q32NS4 — 0.903 Q32NS4 →
Q6PFJ9 — 0.902 Q6PFJ9 →
Q07G17 — 0.902 Q07G17 →
Q9NXU5 — 0.902 Q9NXU5 →
CDC16 Cell division cycle protein 16 homolog 0.902 landscape →
Q28D01 — 0.902 Q28D01 →
Q9CQ33 — 0.902 Q9CQ33 →
Q5RFN0 — 0.902 Q5RFN0 →
B1H1E4 — 0.901 B1H1E4 →
Q8WWQ2 — 0.900 Q8WWQ2 →
P20595 — 0.899 P20595 →
A2VEA3 — 0.899 A2VEA3 →